BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 20932688)

  • 1. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
    Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
    Sher DJ; Wee JO; Punglia RS
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e767-74. PubMed ID: 21300476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Withholding stereotactic radiotherapy in elderly patients with stage I non-small cell lung cancer and co-existing COPD is not justified: outcomes of a Markov model analysis.
    Louie AV; Rodrigues G; Hannouf M; Lagerwaard F; Palma D; Zaric GS; Haasbeek C; Senan S
    Radiother Oncol; 2011 May; 99(2):161-5. PubMed ID: 21620503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    Shah A; Hahn SM; Stetson RL; Friedberg JS; Pechet TT; Sher DJ
    Cancer; 2013 Sep; 119(17):3123-32. PubMed ID: 23720093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
    Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
    J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery.
    Palma D; Visser O; Lagerwaard FJ; Belderbos J; Slotman B; Senan S
    Radiother Oncol; 2011 Nov; 101(2):240-4. PubMed ID: 21775007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer.
    Paix A; Noel G; Falcoz PE; Levy P
    Radiother Oncol; 2018 Sep; 128(3):534-540. PubMed ID: 29706462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer.
    Hamaji M; Chen F; Matsuo Y; Kawaguchi A; Morita S; Ueki N; Sonobe M; Nagata Y; Hiraoka M; Date H
    Ann Thorac Surg; 2015 Apr; 99(4):1122-9. PubMed ID: 25661580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy for stage I non-small cell lung cancer.
    Chang JY; Roth JA
    Thorac Surg Clin; 2007 May; 17(2):251-9. PubMed ID: 17626403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.
    van der Voort van Zyp NC; Prévost JB; van der Holt B; Braat C; van Klaveren RJ; Pattynama PM; Levendag PC; Nuyttens JJ
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):31-7. PubMed ID: 19864077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.
    Robinson CG; DeWees TA; El Naqa IM; Creach KM; Olsen JR; Crabtree TD; Meyers BF; Puri V; Bell JM; Parikh PJ; Bradley JD
    J Thorac Oncol; 2013 Feb; 8(2):192-201. PubMed ID: 23287852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma.
    Nguyen NP; Garland L; Welsh J; Hamilton R; Cohen D; Vinh-Hung V
    Cancer Treat Rev; 2008 Dec; 34(8):719-27. PubMed ID: 18657910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
    Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
    Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of particle therapy in non-small cell lung cancer: exploring decision uncertainty and areas for future research.
    Grutters JP; Pijls-Johannesma M; Ruysscher DD; Peeters A; Reimoser S; Severens JL; Lambin P; Joore MA
    Cancer Treat Rev; 2010 Oct; 36(6):468-76. PubMed ID: 20303217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.
    Kopek N; Paludan M; Petersen J; Hansen AT; Grau C; Høyer M
    Radiother Oncol; 2009 Dec; 93(3):402-7. PubMed ID: 19559492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.